Hovid Rises to Eight-Month High After Agreement With Sanofi Unit

Hovid Bhd., a Malaysian herbal pharmaceutical products maker, surged to an eight-month high in Kuala Lumpur trading after signing an agreement with Winthrop Pharmaceuticals, a unit of Sanofi-Adventis SA, to develop generic drugs.

The stock advanced 21 percent to 23.5 sen at 4:51 p.m. local time, set for its highest close since May 14.

To contact the editor responsible for this story: Chan Tien Hin at thchan@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.